Impact of Sepsis Identification and Treatment Time on In-Hospital Mortality, Length of Stay, and Hours in the Intensive Care Unit

Sylvia EK Sudat, PhD^{1*}

¹Sutter Health Center for Health Systems Research, Division of Research, Development & Dissemination, Walnut Creek, CA, USA

*Corresponding author, keuters@sutterhealth.org

ABSTRACT

Objective: The objective of this study was to examine the impact of timely treatment and identification of sepsis on patient outcomes at Sutter Health, a mixed-payer healthcare system in northern California, US.

Methods: This observational, retrospective analysis considered electronic health record (EHR) data for individuals who presented with sepsis during 2016-17 at any of Sutter Health's 22 emergency departments (ED). Impacts were assessed for the timing of broad-spectrum antibiotic and intravenous (IV) fluid initiation, first vital signs, sepsis screening, and lactate results. Outcomes were in-hospital mortality, hospital length of stay (LOS) and intensive care unit (ICU) hours for patients discharged alive.

Results: The final sample size was 35,847 (N=9,638 severe sepsis, N=5,309 septic shock). Early fluid initiation had the largest estimated impacts: a mortality reduction of 2.85%[2.03%,3.68%] overall and 2.94%[1.44%,4.48%] for severe sepsis (within 1 hour of sepsis presentation), and 14.66%[9.23%,20.07%] for septic shock (within 3 hours); reduced LOS (days) 1.39[1.08,1.71] overall, 2.30[1.31,3.21] severe sepsis, 3.07[1.21,4.94] septic shock; and fewer ICU hours 25.93[16.95,34.66] overall, 35.06[14.7,56.99] severe sepsis, 41.99[15.70,70.68] septic shock (within 3 hours). Sepsis screening within 30 minutes was also associated with mortality reductions (3.88%[2.96%,4.90%] overall, 1.74%[0.08%,3.50%] severe sepsis, 6.78%[3.12%,10.33%] septic shock). The greatest improvement opportunity was estimated for joint initiation of antibiotics and IV fluids, with a modest additional mortality reduction of 0.80%[0.47%,1.17%] overall, 0.77%[0.34%,1.19%] severe sepsis, 2.94%[1.83%,3.97%] septic shock; LOS reduction of 0.37[0.28,0.46] overall, 0.29[0.17,0.43] severe sepsis, 0.25[0.01,0.51] septic shock (within 1 hour); ICU hours reduction of 4.85[3.26,6.57] overall, 5.07[2.55,7.67] severe sepsis, 3.85[1.69,6.24] septic shock (within 3 hours).

INTRODUCTION

Sepsis is a leading cause of in-hospital deaths, and early treatment of sepsis has been recognized as essential in the promotion of better outcomes.^{1,2} Septic patients on average also stay longer in the hospital, and the costs of sepsis management represent a substantial economic burden.^{1,3} The Surviving Sepsis Campaign (survivingsepsis.org) has provided guidance on implementation of 6-hour, 3-hour, and finally 1-hour bundles for sepsis care, and there is evidence that implementation of these guidelines has improved timeliness of sepsis treatment and outcomes for people with sepsis around the world.⁴⁻²⁵ The Center for Medicare and Medicaid Services (CMS) in the US has also established a quality measure for hospitals based on compliance with a sepsis treatment bundle (SEP-1), although the bundle has received criticism, and there does not appear to be evidence that its implementation resulted in improved outcomes for people with sepsis.²⁶⁻³³

This study is a rigorous evaluation of sepsis treatment and identification timing on patient outcomes at 22 hospitals in a large health system during 2016-17. The specific focus is on adult patients whose sepsis onset occurred during or before their time in the emergency department (ED), and who went on to be admitted to the hospital.

Considered in this study were the timing of broad-spectrum antibiotic and intravenous (IV) fluid initiation, first vital signs, documentation of sepsis screening, and initial lactate laboratory test results. The following patient outcomes were measured: in-hospital mortality, hospital length of stay (LOS) for patients discharged alive, and hours spent in the intensive care unit (ICU) for patients who went to the ICU and were discharged alive. Impact was measured in two ways: (1) as the difference between 0% success and 100% success, and (2) as the difference between current practice and 100% success. The second estimate represents the potential opportunity presented for making additional improvements, based on current (2016-17) success rates.

METHODS

Analytical population

Sutter Health is a large, mixed-payer healthcare system in northern California, US. Sutter serves approximately 3.5 million patients per year in both the acute (hospital) and non-acute (e.g. physician office) setting. The analytical population for this study comprises 2016-17 adult hospital admissions at any of Sutter Health's 22 acute care hospitals with emergency departments meeting the following criteria: (1) admission began in the ED, (2) severe sepsis clinical criteria were met (according to vital

signs and lab values, see next section) while in the ED, and (3) treatment with broad-spectrum antibiotics and intravenous (IV) fluids (any volume) was initiated at any point during hospitalization (either while in the ED or after inpatient admission). The following were excluded: transfers from other healthcare facilities/hospitals, admissions for labor and delivery, elective admissions, and non-acute admissions (behavioral health, rehabilitation, and hospice).

Severe sepsis clinical criteria

We followed the CMS definition of severe sepsis – at least two symptoms of systemic inflammatory response syndrome (SIRS), and one symptom of organ dysfunction (see below).²⁶ The definition of sepsis has changed over time; the newest definition no longer relies upon SIRS criteria, and the designation “severe sepsis” has been eliminated.³⁴ However, the older definition is used here because it most closely aligns with hospital definitions of sepsis at the time of this study (2016-17).

For the purposes of this study, the term “sepsis onset” will refer to the first time these clinical criteria were met according to data in the medical record. This has also been referred to as sepsis “time zero.”

SIRS criteria:

- Temperature > 38.3°C or < 36.0°C
- Heart rate > 90
- Respiratory rate > 20 breaths/min or pCO₂ < 32
- White blood cell count > 12,000 or < 4,000 or > 10% bands

Signs of organ dysfunction:

- Systolic blood pressure (SBP) < 90
- Mean arterial pressure (MAP) < 65
- Lactate > 2 mmol/L
- Creatinine > 2 mg/dL
- Bilirubin > 2 mg/dL
- Platelets < 100,000
- INR > 1.5 or aPTT > 60 sec
- Altered mental state (Glasgow coma scale < 15)

qSOFA criteria

Patients are at high risk of adverse outcomes, according to the quick Sequential [Sepsis-related] Organ Failure Assessment (qSOFA),^{34,35} if they meet any two of the following clinical criteria:

- Altered mental state

- Respiratory rate 22 breaths/min or more
- SBP 100 mm Hg or less

The qSOFA was used in statistical models for severity adjustment, as described below.

Statistical methods

The impact of timely treatment was assessed by considering initiation of broad-spectrum antibiotics and IV fluids, both singly and in combination, within 1 and 3 hours of ED arrival and of sepsis onset. Because the focus of this study was the timing of treatment, no restriction was placed on the volume of IV fluids given, only on the timing of fluid initiation. To address the impact of early sepsis identification on outcomes, the following were considered, measured from ED arrival: vital signs taken within 10 minutes, sepsis screening documented within 15 or 30 minutes, and lactate resulted within 1 hour or 3 hours. The patient outcomes considered were in-hospital mortality, hospital LOS for patients discharged alive, and hours spent in the ICU for patients who went to the ICU and were discharged alive.

To assess impact, a counterfactual approach was used.³⁶ Specifically, each outcome was modeled separately, and used to predict the expected result if the treatment or identification event was 100% successful or 0% successful – for example, if all patients were treated with broad-spectrum antibiotics within 1 hour of sepsis onset, versus being treated after 1 hour (G-computation estimator).³⁷ We used logistic regression to model mortality, and negative binomial regression for hospital LOS and hours in the ICU. Separate models (153 in total) were constructed for each treatment/identification variable, outcome, and cohort (full cohort, severe sepsis, and septic shock).

We included the following variables in the outcome models estimating projected outcomes: patient demographics (age category by decade from 60-80+, sex, race, ethnicity), clinical characteristics (comorbidities, Charlson comorbidity index), prior utilization (number of hospitalizations in the prior year, number of ED visits in the prior 6 months), information on prior infection (sepsis diagnosis in the prior year, number of cellulitis diagnoses in the prior year, number of urinary tract infections in the prior year), proxies for severity at presentation (sepsis clinical criteria met at sepsis onset, qSOFA at sepsis onset, time to sepsis onset), and the probability of developing severe sepsis or septic shock based on clinical criteria at sepsis presentation.³⁸⁻⁴⁰ Time to sepsis onset was included as a severity measure because patients with early onset were observed to have higher mortality (see Appendix). The probability of developing severe sepsis or septic shock was modeled separately using logistic

regression. The lactate criterion was excluded from the 18 models estimating impact of time to lactate result.

In each case, we computed two estimates of impact: (1) the difference between 0% success and 100% success, and (2) the difference between current practice and 100% success. Confidence intervals for impact estimates were constructed using the nonparametric bootstrap with 1000 iterations.

RESULTS AND DISCUSSION

The study population is described in Figure 1. Out of a total of 357,012 adult hospital admissions to Sutter Health acute care hospitals in 2016 and 2017, 41,757 (12%) were associated with a sepsis discharge diagnosis unrelated to childbirth or miscarriage. Of these, 253,331 (71%) met basic inclusion criteria (after applying exclusions described in the Methods section), including 39,210 (94%) of sepsis admissions. Severe sepsis clinical criteria were met while in the ED for 51,701 (20%) of all admissions and 20,736 (53%) of sepsis admissions meeting basic inclusion criteria. Finally, 35,847 (69%) of these patients were also treated with broad-spectrum antibiotics and IV fluids during hospitalization, including 19,675 (95%) with sepsis discharge diagnosis. The final study population therefore represents 10% of all 2016-17 adult hospital admissions and 47% of sepsis admissions.

Figure 1. Construction of study population

^a14,581 simple, 18,052 severe, 9,124 shock (discharge diagnosis); ^bTreatment with IV fluids (any volume) and broad-spectrum antibiotics at any point during hospitalization, not necessarily in the ED; ^c4,728 simple, 9,638 severe, 5,309

The overall mortality rate for the study population was 8.58% (5.89% severe sepsis, 24.68% septic shock). Patients were discharged alive for 32,771 admissions (9,068 severe sepsis, 3,999 septic shock), and the average hospital LOS was 6.68 days overall, 6.62 for severe sepsis, and 10.12 for septic shock. ICU stays were part of 10,544 admissions where patients were discharged alive, including 2,395 of those for severe sepsis and 3,488 of those for septic shock. Patients spent on average 89.43

hours in the ICU (76.24 severe sepsis, 109.93 septic shock). Patients were screened for sepsis 99% of the time (N=35,837), and had a documented lactate lab result 93% of the time (N=33,472).

Descriptive data for the N=35,847 full study population are shown in Table 1. Data are summarized by admission, not by unique patient. The cohort was 63.8% white, 11.7% Black/African American, 11.1% Asian, and 2.54% other races. For 10.9% of admissions patient race was unknown or not reported. Hispanic ethnicity was reported for 15.4% of admissions. The most common comorbidities were diabetes without chronic complications (24.4%), congestive heart failure (19.1%), chronic pulmonary disease (25.5%), and renal disease (22.5%). Just over half of admissions were associated with a sepsis discharge diagnosis (13.2% simple, 26.9% severe, 14.8% shock), and 45.1% had no sepsis diagnosis. On average, broad-spectrum antibiotics were administered 2.5 hours (153 minutes) after ED arrival, and just under an hour (58 minutes) after severe sepsis clinical criteria were met (sepsis onset). IV fluids were first given about an hour (66 minutes) after ED arrival, and 5 minutes prior to sepsis onset. The median time to lactate result was 1.5 hours (79 minutes) after arrival in the ED. On average, vital signs were first taken on 5 minutes after arrival, and sepsis screening was documented 8 minutes after arrival.

Tables 2-4 display the estimated impact of treatment with broad-spectrum antibiotics and IV fluids within 1 and 3 hours of sepsis onset (defined as first emergence of severe sepsis clinical criteria in the medical record) on mortality, hospital LOS, and hours in the ICU. Tables 5-7 are analogous to Tables 2-4, but measure time-to-treatment from ED arrival instead of sepsis onset. Finally, Tables 8-10 show the impact on outcomes (mortality, hospital LOS, ICU hours) of the identification-related measures: time to lactate result, time to sepsis screen, and time to first vital sign taken.

Mortality

All versions of treatment within 1 and 3 hours of sepsis onset (Table 2) were found to have a positive impact on mortality, with estimated reductions in mortality rate ranging from 1.01% (antibiotics within 1 hour) to 2.85% (fluids within 1 hour) for the full cohort (N=35,847, mortality rate 8.58%), 1.03% (antibiotics within 1 hour) and 2.94% (fluids within 1 hour) for severe sepsis (N=9,638, mortality rate 5.89%), and from 5.80% (antibiotics within 1 hour) and 14.66% (fluids within 3 hours) for septic shock (N=5,309, mortality rate 24.68%). For all three cohorts, timely initiation of IV fluids was associated with the largest estimated mortality rate reduction.

The greatest opportunity for improvement in current practice, however, was not in the area of IV fluid initiation, because the vast majority of patients (89.8%) were already receiving fluids within 3 hours of sepsis onset (or prior to sepsis onset). The biggest potential gains were estimated to be in the area of increasing the combined initiation of antibiotics and fluids within 1 hour of sepsis onset – only 46.6% of patients (57.3% severe sepsis, 56.7% septic shock) received both treatments within this time frame. For all three cohorts, this combined treatment within 1 hour was associated with the largest mortality reduction as compared to current practice (0.8% for the full cohort, 0.77% for severe sepsis, and 2.94% for septic shock).

Looking at treatment within 1 and 3 hours of ED arrival (Table 5), estimated mortality rate reductions were lower, and less likely to be statistically significant ($p < 0.05$). The largest estimated reductions were still in the area of IV fluid initiation, specifically within 3 hours of ED arrival (2.46% full cohort, 1.96% severe sepsis, 10.65% septic shock). The largest estimated impact of changing current practice was in administering antibiotics and fluids within 3 hours of ED arrival (0.49% mortality reduction overall, 2.04% reduction for septic shock).

Table 8 shows the estimated impact of timely lactate measurement, sepsis screening, and vital signs on mortality. Results suggest that taking vital signs within 10 minutes of ED arrival does not impact the mortality rate for any cohort, nor does receiving lactate test results within 1 hour of ED arrival (for those with a lactate result, $N=33,742$). Lactate results within 3 hours of arrival was associated with a reduction in mortality rate for the full cohort and for septic shock admissions (2.72% and 11.9%, respectively). For the latter, this is the largest estimated impact shown in Table 8. Sepsis screen completion within 30 minutes had the largest estimated impact for the full cohort and for severe sepsis admissions (mortality rate reduction 3.88% and 1.74%, respectively). Despite the high success of early sepsis screening (72.5% within 15 minutes, 86.6% within 30 minutes) and of lactate measurement within 3 hours (81.9%), these areas still showed the largest estimated impacts of a change to current practice, particularly within those who developed septic shock. Within this population, mortality rates could be reduced by an estimated 1.32% by returning lactate results within 3 hours in all cases, and by 0.95% if all sepsis screens were documented within 15 minutes of ED arrival. Within the full cohort, sepsis screening within 15 minutes was also the greatest identified opportunity, with an estimated mortality rate reduction of 0.59% with a change to current practice.

Results displayed in Tables 2, 5, and 8 can also be viewed in the forest plots shown in Figures 2-7.

Hospital length of stay

For patients discharged alive (N=32,771 full cohort, N=9,068 severe sepsis, N=3,999 septic shock), timely treatment in relation to sepsis onset (Table 3) was associated with statistically significant ($p < 0.05$) reductions in hospital LOS (days). For all three cohorts, the largest estimated impact was associated with IV fluid initiation within 3 hours of sepsis onset – an estimated 1.39 fewer days overall, 2.3 days for severe sepsis admissions, and 3.07 days for septic shock. The next largest reduction in hospital LOS was associated with the combined treatment with antibiotics and IV fluids within 3 hours (1.12 days full cohort, 1.36 days severe sepsis, 1.67 days septic shock). The largest impact associated with a change in current practice was in administering both broad-spectrum antibiotics and IV fluids within 1 or 3 hours, for a modest 0.37- or 0.35-day reduction in overall average hospital LOS.

When treatment time was measured from ED arrival (Table 6), IV fluid initiation within 3 hours produced the largest estimated reductions in LOS (0.98 days full cohort, 1.31 days severe sepsis, 2.20 days septic shock); for the septic shock cohort, this was the only estimated impact in Table 6 whose 95% CI did not cross zero. The largest estimate associated with a change in current practice was for combined initiation of IV fluids and antibiotics within 3 hours of ED arrival (in 2016-17 52.6% of the full cohort received both treatments within this time frame), producing an estimated 0.31-day reduction in average LOS.

Table 9 shows that lactate measurement within 3 hours of ED arrival is associated with reduced hospital LOS, among those with a lactate result (N=30,489; N=9,029 severe sepsis, N=3,994 septic shock). The estimated reductions were 1.17 days for the full cohort, 0.96 days for severe sepsis, and 1.22 days for septic shock. Neither measurement of vital signs within 10 minutes or sepsis screening within 15/30 minutes appeared to impact LOS for severe sepsis and septic shock admissions; for the full cohort, sepsis screening within 30 minutes was associated with a modest (0.48-day) LOS reduction. The results in Table 9 do not reveal opportunities for impactful change to current practice – the largest projected LOS reduction is in lactate measurement within 3 hours for the full cohort, associated with an estimated 0.22-day lower average LOS. The results in tables 3, 6, and 9 are compared graphically for the three cohorts in Figures 8-13.

Hours in the intensive care unit

For patients discharged alive who went to the ICU, treatment with IV fluids within 3 hours after sepsis onset was associated with the largest estimated reduction in average hours spent in the ICU (25.93 hours for the full cohort, 35.06 hours for severe sepsis, and 41.99 hours for septic shock) (Table 4). The next most impactful treatment for the full cohort was IV fluid initiation within 1 hour (20.83-hour

reduction); for severe sepsis and septic shock, IV fluids and broad-spectrum antibiotics within 3 hours of sepsis onset was estimated to have the next-largest impact (21.48-hour reduction and 23.5-hour reduction, respectively). For all three cohorts, treatment with IV fluids and antibiotics together within 3 hours of sepsis onset (delivered 69.5% of the time) was the best opportunity for change to current practice, with an estimated intervention effect of 4.85 fewer ICU hours overall, 5.07 for severe sepsis, and 3.85 for septic shock.

When measured from ED arrival (Table 7), IV fluid initiation within 3 hours was still associated with the largest estimated reductions in average ICU hours (23.78 full cohort, 19.06 severe sepsis, 35.66 septic shock). The largest estimated impact of a change to current practice for the full cohort was combined initiation of IV fluids and antibiotics within 3 hours (4.18 fewer hours), for severe sepsis was IV fluid initiation within 1 hour (5.74 fewer hours), and for septic shock was IV fluid initiation within 3 hours (3.36 fewer hours).

As with mortality and hospital LOS, measurement of vital signs within 10 minutes of ED arrival was not found to have an impact on hours spent in the ICU (Table 10). Lactate measurement within 3 hours was associated with an estimated 20.15 fewer ICU hours overall (19.99 severe sepsis, 13.34 septic shock). Lactate measurement within one hour was actually associated with an increase in ICU hours, which is most likely an indication that the 37.1% of admissions that had a lactate resulted very quickly were for sicker individuals. Sepsis screening within 15 and 30 minutes had an estimated impact of 6.04 and 6.93 fewer ICU hours in the full cohort, but none within those with severe sepsis or septic shock. The estimated impact of any change to current practice was small – if the percentage of patients with a lactate resulted within 3 hours of ED arrival increased from 83.2% to 100%, we could see a reduction of 3.49 average hours spent in the ICU (2.99 for severe sepsis, no change for septic shock). Figures 14-19 display the forest plots for Tables 4, 7, and 10.

Study Limitations

This study has several limitations. First, prospective identification of sepsis cases is challenging – as highlighted by the fact that 45.1% of admissions in the study population did not go on to have a sepsis discharge diagnosis. ED clinicians, however, may have to initiate treatment before sepsis has been confirmed, so we have attempted to provide a more complete picture (than would be provided by considering those who have a sepsis discharge diagnosis only) by showing the full cohort of individuals who could have been treated, as well as looking at the subset of admissions that resulted in severe sepsis and septic shock diagnoses. Second, in attempting to include measures of severity of condition

at ED arrival, it was necessary to use time to sepsis onset (according to clinical criteria as described in this report) and the presence or absence of the clinical criteria at sepsis onset as proxies for severity at presentation – even though these values were in reality measured after ED arrival. For estimates that measure time from the door, this could potentially create complications with the time-ordering of events. Given that it is not unreasonable to assume that measured lab values and vital signs simply revealed issues that were present upon ED arrival, this was determined to be an acceptable risk for this analysis, and excluding measures of severity at presentation would have negatively impacted any ability to model the outcomes effectively. Finally, the structure of the analysis does not allow for comparison *between* treatments – for example, to answer the question of what *additional* impact treatment within 1 hour could have over treatment within 3 hours. This could be easily addressed in a future analysis with these data, but was not the focus of this particular study. Given that the focus of this study was on the timing of treatment initiation, the volume of IV fluids given during sepsis treatment was not considered. This is another area of potential future study.

CONCLUSIONS

This analysis suggests that treatment of patients with IV fluids and broad-spectrum antibiotics earlier had a positive impact on patient outcomes at Sutter Health during 2016-17. Prompt sepsis screening appeared to also be making a difference. The greatest opportunity presented, in terms of potential impact if current practice could be altered, was in the area of combined initiation of IV fluids and broad-spectrum antibiotics within one hour of sepsis presentation.

Table 1. Study population descriptive data (N=35,847)

Hispanic ethnicity	15.4%
Race	
<i>White</i>	63.8%
<i>Black/African American</i>	11.7%
<i>Asian</i>	11.1%
<i>Other</i>	2.54%
<i>Unknown</i>	10.9%
Female	50.5%
Age category	
<50	15.9%
50-59	14.6%
60-69	20.3%
70-79	20.7%
80+	28.5%
Trauma admission	1.42%
Charlson comorbidity index (mean)	1.9
Comorbidities	
<i>AIDS/HIV disease</i>	0.55%
Congestive heart failure	19.1%
Chronic pulmonary disease	25.5%
<i>Cerebrovascular disease</i>	9.25%
<i>Dementia</i>	8.46%
<i>Hemiplegia/paraplegia</i>	2.88%
<i>Malignancy</i>	12.4%
<i>Diabetes without chronic complications</i>	24.4%
<i>Myocardial infarction</i>	7.74%
<i>Mild liver disease</i>	8.12%
<i>Metastatic solid tumor</i>	4.49%
<i>Peptic ulcer disease</i>	1.81%
<i>Peripheral vascular disease</i>	10.0%
<i>Rheumatologic disease</i>	3.12%
<i>Renal disease</i>	22.5%
<i>Diabetes with chronic complications</i>	13.6%
<i>Moderate/severe liver disease</i>	2.72%
Sepsis discharge diagnosis	
<i>Simple sepsis</i>	13.2%
<i>Severe sepsis</i>	26.9%
<i>Septic shock</i>	14.8%
<i>No sepsis discharge diagnosis</i>	45.1%
Minutes to broad-spectrum antibiotics (median)	
<i>From ED arrival</i>	153
<i>From clinical criteria met</i>	58
Minutes to IV fluid initiation (median)	
<i>From ED arrival</i>	66
<i>From clinical criteria met</i>	-5
Minutes to lactate result (median)	79
Minutes to sepsis screen (median)	8
Minutes to vitals taken (median)	5

Table 2. Estimated impact of timely treatment on in-hospital mortality, measured from first emergence of severe sepsis symptoms in the medical record.

			Expected mortality by % treated		Expected impact of 100% treatment (95% CI)	
Treatment	Time (from CC)	% treated	0% treated	100% treated	Difference: 0% vs. 100%	Difference: current ^a % treated vs. 100%
Full cohort ^b (N=35,847). 2016-17 mortality: 8.58%						
Broad-spectrum antibiotics	1 hour	51.2%	9.07%	8.06%	-1.01% (-1.65%,-0.40%) ^d	-0.51% (-0.84%,-0.21%) ^d
Broad-spectrum antibiotics	3 hours	74.6%	9.92%	8.11%	-1.80% (-2.56%,-1.12%) ^d	-0.46% (-0.65%,-0.29%) ^d
IV fluids ^c	1 hour	81.1%	10.87%	8.03%	-2.85% (-3.68%,-2.03%) ^d	-0.55% (-0.71%,-0.39%) ^d
IV fluids	3 hours	89.8%	11.08%	8.30%	-2.79% (-3.86%,-1.68%) ^d	-0.28% (-0.39%,-0.17%) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	46.6%	29.23%	7.77%	-1.46% (-2.14%,-0.85%) ^d	-0.80% (-1.17%,-0.47%) ^d
Broad-spectrum antibiotics + IV fluids	3 hours	69.8%	9.97%	7.98%	-1.99% (-2.68%,-1.33%) ^d	-0.60% (-0.80%,-0.40%) ^d
Severe sepsis (N= 9,638). 2016-17 mortality: 5.89%						
Broad-spectrum antibiotics	1 hour	61.5%	6.50%	5.47%	-1.03% (-2.00%,-0.04%) ^d	-0.42% (-0.82%,-0.01%) ^d
Broad-spectrum antibiotics	3 hours	86.2%	6.61%	5.78%	-0.83% (-2.31%,+0.52%)	-0.12% (-0.32%,+0.07%)
IV Fluids	1 hour	86.6%	8.38%	5.44%	-2.94% (-4.48%,-1.44%) ^d	-0.46% (-0.68%,-0.23%) ^d
IV Fluids	3 hours	94.2%	8.41%	5.72%	-2.70% (-4.96%,-0.57%) ^d	-0.18% (-0.33%,-0.04%) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	57.3%	6.83%	5.12%	-1.71% (-2.65%,-0.73%) ^d	-0.77% (-1.19%,-0.34%) ^d
Broad-spectrum antibiotics + IV fluids	3 hours	82.4%	7.08%	5.63%	-1.45% (-2.78%,-0.13%) ^d	-0.26% (-0.49%,-0.02%) ^d
Septic shock (N= 5,309). 2016-17 mortality: 24.68%						
Broad-spectrum antibiotics	1 hour	60.3%	28.12%	22.32%	-5.80% (-8.48%,-3.43%) ^d	-2.36% (-3.42%,-1.40%) ^d
Broad-spectrum antibiotics	3 hours	85.6%	33.02%	23.24%	-9.79% (-13.48%,-6.01%) ^d	-1.44% (-2.00%,-0.89%) ^d
IV fluids	1 hour	87.1%	33.00%	23.37%	-9.64% (-13.13%,-6.09%) ^d	-1.31% (-1.78%,-0.83%) ^d
IV fluids	3 hours	94.9%	38.56%	23.89%	-14.66% (-20.07%,-9.23%) ^d	-0.78% (-1.09%,-0.49%) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	56.7%	28.37%	21.74%	-6.63% (-9.05%,-4.19%) ^d	-2.94% (-3.97%,-1.83%) ^d
Broad-spectrum antibiotics + IV fluids	3 hours	83.0%	33.56%	22.81%	-10.75% (-14.36%,-7.28%) ^d	-1.86% (-2.46%,-1.26%) ^d

CC=severe sepsis clinical criteria met; CI=confidence interval; ED=emergency department; IV=intravenous

^a2016-2017; ^bAny admission where (1) severe sepsis clinical criteria were met while in the ED, and (2) patient was treated with broad-spectrum antibiotics and IV fluids (any volume) at some point during hospitalization; ^cAny volume; ^dStatistically significant (p<0.05)

Table 3. Estimated impact of timely treatment on mean hospital LOS (days) for patients discharged alive, measured from first emergence of severe sepsis symptoms in the medical record.

			Expected mean hospital LOS by % treated		Expected impact of 100% treatment (95% CI)	
Treatment	Time (from CC)	% treated	0% treated	100% treated	Difference: 0% vs. 100%	Difference: current ^a % treated vs. 100%
Full cohort ^b (N= 32,771). 2016-17 mean hospital LOS: 6.68 days						
Broad-spectrum antibiotics	1 hour	51.6%	6.96	6.39	-0.57 (-0.73,-0.41) ^d	-0.28 (-0.36,-0.20) ^d
Broad-spectrum antibiotics	3 hours	75.0%	7.44	6.40	-1.04 (-1.25,-0.83) ^d	-0.27 (-0.33,-0.22) ^d
IV fluids ^c	1 hour	81.5%	7.47	6.49	-0.98 (-1.22,-0.74) ^d	-0.19 (-0.23,-0.14) ^d
IV fluids	3 hours	90.1%	7.92	6.53	-1.39 (-1.71,-1.08) ^d	-0.14 (-0.18,-0.11) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	47.1%	6.99	6.30	-0.69 (-0.85,-0.53) ^d	-0.37 (-0.46,-0.28) ^d
Broad-spectrum antibiotics + IV fluids	3 hours	70.2%	7.45	6.33	-1.12 (-1.33,-0.92) ^d	-0.35 (-0.41,-0.28) ^d
Severe sepsis (N= 9,068). 2016-17 mean hospital LOS: 6.62 days						
Broad-spectrum antibiotics	1 hour	61.9%	6.91	6.42	-0.50 (-0.83,-0.18) ^d	-0.20 (-0.33,-0.08) ^d
Broad-spectrum antibiotics	3 hours	86.3%	7.66	6.43	-1.23 (-1.78,-0.74) ^d	-0.19 (-0.27,-0.12) ^d
IV Fluids	1 hour	87.1%	7.74	6.43	-1.31 (-1.98,-0.70) ^d	-0.18 (-0.28,-0.10) ^d
IV Fluids	3 hours	94.4%	8.77	6.47	-2.30 (-3.21,-1.31) ^d	-0.14 (-0.21,-0.08) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	57.9%	6.99	6.32	-0.67 (-0.97,-0.37) ^d	-0.29 (-0.43,-0.17) ^d
Broad-spectrum antibiotics + IV fluids	3 hours	82.7%	7.72	6.36	-1.36 (-1.82,-0.93) ^d	-0.25 (-0.35,-0.17) ^d
Septic shock (N= 3,999). 2016-17 mean hospital LOS: 10.12 days						
Broad-spectrum antibiotics	1 hour	62.5%	10.26	10.02	-0.24 (-0.88,+0.35)	-0.10 (-0.34,+0.12)
Broad-spectrum antibiotics	3 hours	87.4%	11.27	9.93	-1.34 (-2.30,-0.40) ^d	-0.19 (-0.32,-0.06) ^d
IV fluids	1 hour	88.9%	11.47	9.94	-1.53 (-2.56,-0.51) ^d	-0.19 (-0.32,-0.07) ^d
IV fluids	3 hours	96.0%	13.05	9.98	-3.07 (-4.94,-1.21) ^d	-0.14 (-0.24,-0.06) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	59.3%	10.45	9.87	-0.58 (-1.18,+0.01)	-0.25 (-0.51,-0.01) ^d
Broad-spectrum antibiotics + IV fluids	3 hours	85.2%	11.52	9.85	-1.67 (-2.58,-0.72) ^d	-0.27 (-0.43,-0.12) ^d

CC=severe sepsis clinical criteria met; CI=confidence interval; ED=emergency department; IV=intravenous; LOS=length of stay

^a2016-2017; ^bAny admission where (1) severe sepsis clinical criteria were met while in the ED, and (2) patient was treated with broad-spectrum antibiotics and IV fluids (any volume) at some point during hospitalization; ^cAny volume; ^dStatistically significant (p<0.05)

Table 4. Estimated impact of timely treatment on hours in the ICU, measured from first emergence of severe sepsis symptoms in the medical record.

			Expected mean ICU hours by % treated		Expected impact of 100% treatment (95% CI)	
Treatment	Time (from CC)	% treated	0% treated	100% treated	Difference: 0% vs. 100%	Difference: current ^a % treated vs. 100%
Full cohort ^b (N=10,544). 2016-17 mean time in ICU: 89.43 hours						
Broad-spectrum antibiotics	1 hour	50.8%	91.34	87.42	-3.93 (-8.83,+0.10)	-2.01 (-4.43,+0.01)
Broad-spectrum antibiotics	3 hours	73.8%	97.67	86.24	-11.43 (-17.04,-6.83) ^d	-3.19 (-4.73,-1.96) ^d
IV fluids ^c	1 hour	81.7%	106.32	85.49	-20.83 (-27.24,-14.57) ^d	-3.94 (-5.18,-2.78) ^d
IV fluids	3 hours	90.2%	112.7	86.77	-25.93 (-34.66,-16.95) ^d	-2.66 (-3.57,-1.78) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	46.4%	92.80	85.27	-7.53 (-12.43,-3.29) ^d	-4.16 (-6.87,-1.84) ^d
Broad-spectrum antibiotics + IV fluids	3 hours	69.5%	99.72	84.58	-15.14 (-20.64,-10.13) ^d	-4.85 (-6.57,-3.26) ^d
Severe sepsis (N=2,395). 2016-17 mean time in ICU: 76.24 hours						
Broad-spectrum antibiotics	1 hour	61.3%	76.92	74.9	-2.02 (-11.25,+5.33)	-1.34 (-4.87,+1.51)
Broad-spectrum antibiotics	3 hours	84.6%	86.11	73.67	-12.44 (-24.75,-1.89) ^d	-2.57 (-4.97,-0.68) ^d
IV Fluids	1 hour	84.8%	90.83	72.81	-18.01 (-29.87,-6.27) ^d	-3.42 (-5.73,-1.4) ^d
IV Fluids	3 hours	92.2%	107.88	72.81	-35.06 (-56.99,-14.7) ^d	-3.42 (-5.62,-1.52) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	55.9%	80.32	71.96	-8.36 (-16.89,-0.92) ^d	-4.28 (-8.02,-0.78) ^d
Broad-spectrum antibiotics + IV fluids	3 hours	79.6%	92.65	71.17	-21.48 (-32.86,-10.37) ^d	-5.07 (-7.67,-2.55) ^d
Septic shock (N=3,488). 2016-17 mean time in ICU: 109.93 hours						
Broad-spectrum antibiotics	1 hour	62.8%	109.84	109.71	-0.13 (-8.90,+8.19)	-0.22 (-3.74,+3.05)
Broad-spectrum antibiotics	3 hours	87.5%	121.4	107.95	-13.44 (-27.08,-0.58) ^d	-1.98 (-3.92,-0.29) ^d
IV fluids	1 hour	88.7%	128.16	107.3	-20.86 (-37.00,-5.88) ^d	-2.64 (-4.82,-0.82) ^d
IV fluids	3 hours	95.9%	149.9	107.91	-41.99 (-70.68,-15.70) ^d	-2.02 (-3.53,-0.88) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	59.4%	112.6	107.71	-4.89 (-13.61,+4.57)	-2.22 (-6.03,+1.67)
Broad-spectrum antibiotics + IV fluids	3 hours	85.3%	129.58	106.08	-23.5 (-37.36,-10.01) ^d	-3.85 (-6.24,-1.69) ^d

CC=severe sepsis clinical criteria met; CI=confidence interval; ED=emergency department; ICU=intensive care unit; IV=intravenous

Analysis includes patients discharged alive who went to the ICU at some point during hospitalization.

^a2016-2017; ^bAny admission where (1) severe sepsis clinical criteria were met while in the ED, and (2) patient was treated with broad-spectrum antibiotics and IV fluids (any volume) at some point during hospitalization; ^cAny volume; ^dStatistically significant (p<0.05)

Table 5. Estimated impact of timely treatment on in-hospital mortality, measured from ED arrival.

			Expected mortality by % treated		Expected impact of 100% treatment (95% CI)	
Treatment	Time (from ED-A)	% treated	0% treated	100% treated	Difference: 0% vs. 100%	Difference: current ^a % treated vs. 100%
Full cohort ^b (N=35,847). 2016-17 mortality: 8.58%						
Broad-spectrum antibiotics	1 hour	13.50%	8.47%	9.15%	+0.68% (-0.16%,+1.53%)	+0.57% (-0.13%,+1.28%)
Broad-spectrum antibiotics	3 hours	57.30%	9.20%	8.19%	-1.01% (-1.67%,-0.38%) ^d	-0.38% (-0.63%,-0.15%) ^d
IV fluids ^c	1 hour	46.70%	8.58%	8.57%	-0.01% (-0.60%,+0.62%)	-0.01% (-0.28%,+0.29%)
IV fluids	3 hours	81.20%	10.65%	8.20%	-2.46% (-3.37%,-1.56%) ^d	-0.38% (-0.52%,-0.24%) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	11.80%	8.52%	8.91%	0.39% (-0.53%,+1.27%)	+0.33% (-0.46%,+1.1%)
Broad-spectrum antibiotics + IV fluids	3 hours	52.80%	9.25%	8.08%	-1.17% (-1.82%,-0.6%) ^d	-0.49% (-0.76%,-0.25%) ^d
Severe sepsis (N= 9,638). 2016-17 mortality: 5.89%						
Broad-spectrum antibiotics	1 hour	17.80%	5.82%	6.21%	0.39% (-0.82%,+1.61%)	0.31% (-0.66%,+1.30%)
Broad-spectrum antibiotics	3 hours	71.40%	6.13%	5.81%	-0.32% (-1.46%,+0.77%)	-0.08% (-0.39%,+0.20%)
IV Fluids	1 hour	51.20%	6.20%	5.62%	-0.58% (-1.54%,+0.44%)	-0.27% (-0.72%,+0.21%)
IV Fluids	3 hours	87.40%	7.62%	5.66%	-1.96% (-3.64%,-0.36%) ^d	-0.24% (-0.42%,-0.04%) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	15.70%	5.95%	5.61%	-0.34% (-1.54%,+0.95%)	-0.28% (-1.28%,+0.79%)
Broad-spectrum antibiotics + IV fluids	3 hours	67.10%	6.46%	5.64%	-0.82% (-1.87%,+0.25%)	-0.25% (-0.57%,+0.08%)
Septic shock (N=5,309). 2016-17 mortality: 24.68%						
Broad-spectrum antibiotics	1 hour	23.70%	25.02%	23.58%	-1.44% (-4.28%,+1.24%)	-1.09% (-3.26%,+0.95%)
Broad-spectrum antibiotics	3 hours	74.70%	30.53%	22.80%	-7.74% (-10.83%,-4.94%) ^d	-1.88% (-2.61%,-1.19%) ^d
IV fluids	1 hour	61.80%	26.91%	23.34%	-3.58% (-6.01%,-1.17%) ^d	-1.34% (-2.24%,-0.44%) ^d
IV fluids	3 hours	90.40%	34.34%	23.70%	-10.65% (-15.46%,-6.21%) ^d	-0.98% (-1.42%,-0.57%) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	21.40%	25.03%	23.38%	-1.65% (-4.48%,+1.14%)	-1.29% (-3.53%,+0.90%)
Broad-spectrum antibiotics + IV fluids	3 hours	71.80%	30.15%	22.63%	-7.52% (-10.54%,-4.93%) ^d	-2.04% (-2.87%,-1.32%) ^d

CI=confidence interval; ED=emergency department; ED-A=ED arrival; IV=intravenous

^a2016-2017; ^bAny admission where (1) severe sepsis clinical criteria were met while in the ED, and (2) patient was treated with broad-spectrum antibiotics and IV fluids (any volume) at some point during hospitalization; ^cAny volume; ^dStatistically significant (p<0.05)

Table 6. Estimated impact of timely treatment on mean hospital LOS (days) for patients discharged alive, measured from ED arrival.

			Expected mean hospital LOS by % treated		Expected impact of 100% treatment (95% CI)	
Treatment	Time (from ED-A)	% treated	0% treated	100% treated	Difference: 0% vs. 100%	Difference: current ^a % treated vs. 100%
Full cohort ^b (N= 32,771). 2016-17 mean hospital LOS: 6.68 days						
Broad-spectrum antibiotics	1 hour	13.2%	6.68	6.61	-0.08 (-0.27,+0.12)	-0.07 (-0.24,+0.10)
Broad-spectrum antibiotics	3 hours	57.0%	6.98	6.44	-0.55 (-0.74,-0.36) ^d	-0.24 (-0.32,-0.16) ^d
IV fluids ^c	1 hour	46.1%	6.79	6.55	-0.24 (-0.41,-0.07) ^d	-0.13 (-0.22,-0.04) ^d
IV fluids	3 hours	81.2%	7.46	6.49	-0.98 (-1.25,-0.72) ^d	-0.19 (-0.24,-0.14) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	11.5%	6.69	6.52	-0.17 (-0.38,+0.05)	-0.15 (-0.34,+0.04)
Broad-spectrum antibiotics + IV fluids	3 hours	52.6%	7.01	6.37	-0.64 (-0.83,-0.46) ^d	-0.31 (-0.40,-0.22) ^d
Severe sepsis (N=9,068). 2016-17 mean hospital LOS: 6.62 days						
Broad-spectrum antibiotics	1 hour	17.6%	6.64	6.48	-0.16 (-0.45,+0.18)	-0.14 (-0.38,+0.14)
Broad-spectrum antibiotics	3 hours	71.3%	7.04	6.43	-0.61 (-1.03,-0.24) ^d	-0.19 (-0.32,-0.08) ^d
IV Fluids	1 hour	51.3%	6.73	6.49	-0.24 (-0.54,+0.08)	-0.12 (-0.29,+0.03)
IV Fluids	3 hours	87.6%	7.74	6.44	-1.31 (-2.08,-0.66) ^d	-0.18 (-0.28,-0.09) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	15.7%	6.65	6.41	-0.24 (-0.54,+0.11)	-0.21 (-0.47,+0.08)
Broad-spectrum antibiotics + IV fluids	3 hours	67.2%	7.09	6.36	-0.73 (-1.13,-0.38) ^d	-0.26 (-0.39,-0.14) ^d
Septic shock (N=3,999). 2016-17 mean hospital LOS: 10.12 days						
Broad-spectrum antibiotics	1 hour	24.1%	10.19	9.87	-0.31 (-0.95,+0.31)	-0.25 (-0.73,+0.23)
Broad-spectrum antibiotics	3 hours	76.1%	10.30	10.05	-0.25 (-1.02,+0.47)	-0.07 (-0.27,+0.11)
IV fluids	1 hour	62.7%	10.34	9.97	-0.38 (-1.06,+0.27)	-0.15 (-0.43,+0.08)
IV fluids	3 hours	91.4%	12.10	9.91	-2.20 (-3.69,-0.84) ^d	-0.21 (-0.36,-0.09) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	21.8%	10.19	9.81	-0.38 (-1.03,+0.26)	-0.31 (-0.83,+0.19)
Broad-spectrum antibiotics + IV fluids	3 hours	73.3%	10.51	9.96	-0.55 (-1.30,+0.15)	-0.16 (-0.37,+0.02)

CI=confidence interval; ED=emergency department; ED-A=ED arrival; IV=intravenous

^a2016-2017; ^bAny admission where (1) severe sepsis clinical criteria were met while in the ED, and (2) patient was treated with broad-spectrum antibiotics and IV fluids (any volume) at some point during hospitalization; ^cAny volume; ^dStatistically significant (p<0.05)

Table 7. Estimated impact of timely treatment on hours in the ICU, measured from ED arrival.

			Expected mean ICU hours by % treated		Expected impact of 100% treatment (95% CI)	
Treatment	Time (from ED-A)	% treated	0% treated	100% treated	Difference: 0% vs. 100%	Difference: current ^a % treated vs. 100%
Full cohort ^b (N= 10,544). 2016-17 mean time in ICU: 89.43 hours						
Broad-spectrum antibiotics	1 hour	17.6%	89.65	88.25	-1.41 (-6.85,+4.25)	-1.18 (-5.71,+3.51)
Broad-spectrum antibiotics	3 hours	61.0%	93.12	86.88	-6.24 (-11.93,-1.29) ^d	-2.55 (-4.83,-0.58) ^d
IV fluids ^c	1 hour	54.6%	93.38	86.07	-7.31 (-12.08,-3.02) ^d	-3.36 (-5.55,-1.44) ^d
IV fluids	3 hours	84.0%	109.33	85.55	-23.78 (-32.35,-16.09) ^d	-3.88 (-5.31,-2.64) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	15.3%	89.98	86.19	-3.79 (-9.22,+2.13)	-3.24 (-7.87,+1.79)
Broad-spectrum antibiotics + IV fluids	3 hours	56.6%	94.58	85.25	-9.33 (-14.60,-4.73) ^d	-4.18 (-6.49,-2.10) ^d
Severe sepsis (N=2,395). 2016-17 mean time in ICU: 76.24 hours						
Broad-spectrum antibiotics	1 hour	21.9%	75.70	75.73	+0.03 (-7.68,+9.31)	-0.51 (-6.95,+6.83)
Broad-spectrum antibiotics	3 hours	72.4%	83.88	72.50	-11.38 (-22.09,-1.62) ^d	-3.74 (-6.74,-0.79) ^d
IV Fluids	1 hour	55.2%	81.78	70.50	-11.28 (-18.13,-3.97) ^d	-5.74 (-9.43,-2.12) ^d
IV Fluids	3 hours	86.6%	92.07	73.01	-19.06 (-33.18,-5.34) ^d	-3.23 (-5.54,-1.1) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	19.0%	76.36	72.82	-3.54 (-11.91,+5.64)	-3.42 (-10.02,+4.27)
Broad-spectrum antibiotics + IV fluids	3 hours	67.0%	85.66	70.69	-14.98 (-24.69,-5.44) ^d	-5.55 (-8.9,-1.98) ^d
Septic shock (N=3,488). 2016-17 mean time in ICU: 109.93 hours						
Broad-spectrum antibiotics	1 hour	24.8%	110.13	108.61	-1.51 (-11.37,+9.36)	-1.32 (-8.9,+6.77)
Broad-spectrum antibiotics	3 hours	76.5%	110.22	109.61	-0.61 (-12.08,+10.43)	-0.32 (-3.4,+2.39)
IV fluids	1 hour	63.1%	111.12	108.93	-2.20 (-12.92,+6.81)	-1.01 (-5.05,+2.27)
IV fluids	3 hours	91.5%	142.24	106.57	-35.66 (-60.29,-14.5) ^d	-3.36 (-5.95,-1.52) ^d
Broad-spectrum antibiotics + IV fluids	1 hour	22.4%	110.68	106.49	-4.19 (-13.93,+6.15)	-3.45 (-11.06,+4.36)
Broad-spectrum antibiotics + IV fluids	3 hours	73.7%	115.29	107.63	-7.66 (-18.19,+3.38)	-2.3 (-5.34,+0.74)

CI=confidence interval; ED=emergency department; ED-A=ED arrival; IV=intravenous

Analysis includes patients discharged alive who went to the ICU at some point during hospitalization.

^a2016-2017; ^bAny admission where (1) severe sepsis clinical criteria were met while in the ED, and (2) patient was treated with broad-spectrum antibiotics and IV fluids (any volume) at some point during hospitalization; ^cAny volume; ^dStatistically significant (p<0.05)

Table 8. Estimated impact of timely lactate measurement, sepsis screening, and vital signs on in-hospital mortality.

			Expected mortality by % success		Expected impact if 100% successful (95% CI)	
Measure	Time (from ED-A)	Current ^a %	0%	100%	Difference: 0% vs. 100%	Difference: current % vs. 100%
Full cohort ^b (N= 35,837). 2016-17 mortality: 8.56%						
Lactate resulted ^c	1 hour	33.2%	8.69%	9.27%	+0.58% (-0.06%,+1.2%)	+0.36% (-0.04%,+0.76%)
Lactate resulted	3 hours	81.9%	11.22%	8.50%	-2.72% (-3.74%,-1.79%) ^f	-0.40% (-0.55%,-0.27%) ^f
Sepsis screen completed	15 minutes	72.5%	10.16%	7.97%	-2.19% (-2.86%,-1.52%) ^f	-0.59% (-0.77%,-0.41%) ^f
Sepsis screen completed	30 minutes	86.6%	11.93%	8.05%	-3.88% (-4.90%,-2.96%) ^f	-0.51% (-0.65%,-0.39%) ^f
Vital signs taken	10 minutes	76.7%	8.67%	8.55%	-0.13% (-0.80%,+0.61%)	-0.03% (-0.17%,+0.13%)
Severe sepsis (N=9,637). 2016-17 mortality: 5.88%						
Lactate resulted ^d	1 hour	38.6%	6.23%	5.42%	-0.82% (-1.80%,+0.23%)	-0.47% (-1.04%,+0.14%)
Lactate resulted	3 hours	87.8%	6.88%	5.77%	-1.11% (-2.79%,+0.52%)	-0.11% (-0.28%,+0.06%)
Sepsis screen completed	15 minutes	75.1%	6.81%	5.60%	-1.22% (-2.48%,-0.15%) ^f	-0.29% (-0.58%,-0.03%) ^f
Sepsis screen completed	30 minutes	89.4%	7.45%	5.71%	-1.74% (-3.50%,-0.08%) ^f	-0.17% (-0.34%,-0.01%) ^f
Vital signs taken	10 minutes	76.1%	6.28%	5.78%	-0.50% (-1.66%,+0.54%)	-0.11% (-0.37%,+0.12%)
Septic shock (N=5,307). 2016-17 mortality: 24.67%						
Lactate resulted ^e	1 hour	41.0%	24.97%	24.13%	-0.84% (-3.33%,+1.56%)	-0.49% (-1.90%,+0.90%)
Lactate resulted	3 hours	88.0%	35.19%	23.30%	-11.9% (-16.69%,-7.65%) ^f	-1.32% (-1.83%,-0.86%) ^f
Sepsis screen completed	15 minutes	73.5%	27.28%	23.72%	-3.57% (-6.13%,-0.96%) ^f	-0.95% (-1.62%,-0.26%) ^f
Sepsis screen completed	30 minutes	87.5%	30.58%	23.80%	-6.78% (-10.33%,-3.12%) ^f	-0.86% (-1.30%,-0.40%) ^f
Vital signs taken	10 minutes	79.0%	24.67%	24.68%	0.00% (-2.73%,+2.88%)	0.00% (-0.57%,+0.59%)

CI=confidence interval; ED=emergency department; ED-A=ED arrival

^a2016-2017; ^bAny admission where (1) severe sepsis clinical criteria were met while in the ED, and (2) patient was treated with broad-spectrum antibiotics and IV fluids (any volume) at some point during hospitalization; ^cN=33,472, mortality 8.91%; ^dN=9,596, mortality 8.58%; ^eN=5,298, mortality 24.61%; ^fStatistically significant (p<0.05)

Table 9. Estimated impact of timely lactate measurement, sepsis screening, and vital signs on hospital length of stay (days) for patients discharged alive.

			Expected mean hospital LOS by % success		Expected impact if 100% successful (95% CI)	
Measure	Time (from ED-A)	Current ^a %	0%	100%	Difference: 0% vs. 100%	Difference: current % vs. 100%
Full cohort ^b (N= 32,767). 2016-17 mean hospital LOS: 6.68 days						
Lactate resulted ^c	1 hour	32.6%	6.78	6.69	-0.10 (-0.28,+0.09)	-0.07 (-0.19,+0.06)
Lactate resulted	3 hours	82.0%	7.70	6.54	-1.17 (-1.48,-0.87) ^f	-0.22 (-0.27,-0.16) ^f
Sepsis screen completed	15 minutes	72.9%	6.77	6.64	-0.13 (-0.32,+0.04)	-0.04 (-0.09,+0.01)
Sepsis screen completed	30 minutes	87.1%	7.09	6.61	-0.48 (-0.78,-0.21) ^f	-0.07 (-0.11,-0.03) ^f
Vital signs taken	10 minutes	76.5%	6.57	6.71	0.14 (-0.05,+0.33)	0.03 (-0.01,+0.08)
Severe sepsis (N=9,068). 2016-17 mean hospital LOS: 6.62 days						
Lactate resulted ^d	1 hour	38.6%	6.71	6.46	-0.25 (-0.54,+0.07)	-0.16 (-0.34,+0.04)
Lactate resulted	3 hours	87.8%	7.45	6.49	-0.96 (-1.61,-0.28) ^f	-0.13 (-0.22,-0.04) ^f
Sepsis screen completed	15 minutes	75.2%	6.59	6.62	+0.02 (-0.31,+0.33)	0.00 (-0.08,+0.07)
Sepsis screen completed	30 minutes	89.5%	6.82	6.59	-0.23 (-0.70,+0.22)	-0.03 (-0.08,+0.01)
Vital signs taken	10 minutes	76.0%	6.42	6.67	+0.26 (-0.08,+0.54)	0.06 (-0.03,+0.12)
Septic shock (N=3,998). 2016-17 mean hospital LOS: 10.12 days						
Lactate resulted ^e	1 hour	40.7%	10.12	10.13	+0.01 (-0.59,+0.61)	0.00 (-0.37,+0.35)
Lactate resulted	3 hours	89.1%	11.2	9.97	-1.22 (-2.45,-0.13) ^f	-0.15 (-0.30,-0.03) ^f
Sepsis screen completed	15 minutes	74.6%	9.85	10.21	+0.36 (-0.31,+1.02)	+0.09 (-0.10,+0.25)
Sepsis screen completed	30 minutes	88.6%	10.02	10.13	+0.11 (-0.69,+0.91)	+0.01 (-0.11,+0.10)
Vital signs taken	10 minutes	78.9%	9.68	10.24	+0.56 (-0.12,+1.21)	+0.12 (-0.04,+0.26)

CI=confidence interval; ED=emergency department; ED-A=ED arrival; IV=intravenous

^a2016-2017; ^bAny admission where (1) severe sepsis clinical criteria were met while in the ED, and (2) patient was treated with broad-spectrum antibiotics and IV fluids (any volume) at some point during hospitalization; ^cN=30,489, mean LOS 6.75 days; ^dN=9,029, mean LOS 6.62 days; ^eN=3,994, mean LOS 10.13 days; ^fStatistically significant (p<0.05)

Table 10. Estimated impact of timely lactate measurement and sepsis screening on hours spent in the ICU.

			Expected mean ICU hours by % success		Expected impact if 100% successful (95% CI)	
Measure	Time (from ED-A)	Current ^a %	0%	100%	Difference: 0% vs. 100%	Difference: current % vs. 100%
Full cohort ^b (N=10,543). 2016-17 mean time in ICU: 89.44 hours						
Lactate resulted ^c	1 hour	37.1%	88.45	93.24	+4.79 (+0.13,+9.69) ^f	+3.06 (+0.09,+6.17) ^f
Lactate resulted	3 hours	83.2%	106.88	86.73	-20.15 (-27.95,-11.91) ^f	-3.46 (-4.90,-2.09) ^f
Sepsis screen completed	15 minutes	71.7%	93.69	87.64	-6.04 (-10.83,-1.46) ^f	-1.80 (-3.21,-0.47) ^f
Sepsis screen completed	30 minutes	84.9%	95.22	88.29	-6.93 (-13.18,-1.60) ^f	-1.15 (-2.20,-0.28) ^f
Vital signs taken	10 minutes	79.4%	89.01	89.52	+0.51 (-5.13,+5.87)	+0.09 (-1.11,+1.18)
Severe sepsis (N=2,395). 2016-17 mean time in ICU: 76.24 hours						
Lactate resulted ^d	1 hour	39.2%	72.28	81.34	+9.06 (+1.38,+16.49) ^f	+5.16 (+0.25,+9.97) ^f
Lactate resulted	3 hours	87.6%	93.18	73.2	-19.99 (-35.00,-3.97) ^f	-2.99 (-5.74,-0.69) ^f
Sepsis screen completed	15 minutes	74.1%	78.81	74.61	-4.2 (-12.91,+3.42)	-1.63 (-4.10,+0.34)
Sepsis screen completed	30 minutes	87.5%	81.3	74.89	-6.41 (-18.3,+2.49)	-1.35 (-3.25,-0.03) ^f
Vital signs taken	10 minutes	78.8%	73.54	76.26	+2.72 (-6.32,+10.66)	0.02 (-2.08,+1.73)
Septic shock (N=3,487). 2016-17 mean time in ICU: 109.96 hours						
Lactate resulted ^e	1 hour	40.4%	104.28	118.35	+14.07 (+5.32,+23.41) ^f	+8.39 (+2.96,+13.99) ^f
Lactate resulted	3 hours	89.3%	121.61	108.27	-13.34 (-32.92,+4.97)	-1.69 (-4.15,+0.29)
Sepsis screen completed	15 minutes	74.5%	111.11	109.33	-1.78 (-13.21,+8.84)	-0.64 (-3.71,+2.00)
Sepsis screen completed	30 minutes	88.5%	107.24	110.15	+2.91 (-10.32,+14.45)	+0.18 (-1.63,+1.57)
Vital signs taken	10 minutes	79.1%	111.32	109.35	-1.97 (-13.22,+9.31)	-0.59 (-3.22,+1.86)

CI=confidence interval; ED=emergency department; ED-A=ED arrival; IV=intravenous

Analysis includes patients discharged alive who went to the ICU at some point during hospitalization.

^a2016-2017; ^bAny admission where (1) severe sepsis clinical criteria were met while in the ED, and (2) patient was treated with broad-spectrum antibiotics and IV fluids (any volume) at some point during hospitalization; ^cN=10,113, mean ICU hours 90.19; ^dN=2,390, mean ICU hours 76.18; ^eN=3,484, mean ICU hours 109.96; ^fStatistically significant (p<0.05)

Figure 2. Estimated opportunity to impact in-hospital mortality (100% success vs. current %). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Full cohort; sepsis screen/vital signs N=35,837, lactate resulted N=33,472, otherwise N=35,847. Data detail in Tables 2, 5, and 8.

Figure 3. Estimated impact of timely identification and treatment on in-hospital mortality (100% success vs. 0% success). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Full cohort; sepsis screen/vital signs N=35,837, lactate resulted N=33,472, otherwise N=35,847. Data detail in Tables 2, 5, and 8.

Figure 4. Estimated opportunity to impact in-hospital mortality (100% success vs. current %). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Severe sepsis cohort; sepsis screen/vital signs N=9.637, lactate resulted N=9.596, otherwise N=9.638. Data detail in Tables 2, 5, and 8.

Figure 5. Estimated impact of timely identification and treatment on in-hospital mortality (100% success vs. 0% success). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Severe sepsis cohort; sepsis screen/vital signs N=9.637, lactate resulted N=9.596, otherwise N=9.638. Data detail in Tables 2, 5, and 8.

Figure 6. Estimated opportunity to impact in-hospital mortality (100% success vs. current %). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Septic shock cohort; sepsis screen/vital signs N=5,307, lactate resulted N=5,298, otherwise N=5,309. Data detail in Tables 2, 5, and 8.

Figure 7. Estimated impact of timely identification and treatment on in-hospital mortality (100% success vs. 0% success). Septic shock cohort; sepsis screen/vital signs N=5,307, lactate resulted N=5,298, otherwise N=5,309. Data detail in Tables 2, 5, and 8.

Figure 8. Estimated opportunity to impact hospital length of stay (days) for patients discharged alive (100% success vs. current %). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Full cohort; sepsis screen/vital signs N=32,767, lactate resulted N=30,489, otherwise N=32,771. Data detail in Tables 3, 6, and 9.

Figure 9. Estimated impact of timely identification and treatment on hospital length of stay (days) for patients discharged alive (100% success vs. 0% success). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Full cohort; sepsis screen/vital signs N=32,767, lactate resulted N=30,489, otherwise N=32,771. Data detail in Tables 3, 6, and 9.

Figure 10. Estimated opportunity to impact hospital length of stay (days) for patients discharged alive (100% success vs. current %). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Severe sepsis cohort; lactate resulted N=9,029, otherwise N=9,068. Data detail in Tables 3, 6, and 9.

Figure 11. Estimated impact of timely identification and treatment on hospital length of stay (days) for patients discharged alive (100% success vs. 0% success). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Severe sepsis cohort; lactate resulted N=9,029, otherwise N=9,068. Data detail in Tables 3, 6, and 9.

Figure 12. Estimated opportunity to impact hospital length of stay (days) for patients discharged alive (100% success vs. current %). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Septic shock cohort; sepsis screen/vital signs N=3,998, lactate resulted N=3,994, otherwise N=3,999. Data detail in Tables 3, 6, and 9.

Figure 13. Estimated impact of timely identification and treatment on hospital length of stay (days) for patients discharged alive (100% success vs. 0% success). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Septic shock cohort; sepsis screen/vital signs N=3,998, lactate resulted N=3,994, otherwise N=3,999. Data detail in Tables 3, 6, and 9.

Figure 14. Estimated opportunity to impact hours spent in the ICU for patients discharged alive (100% success vs. current %). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Full cohort; sepsis screen/vital signs N=10,543, lactate resulted N=10,113, otherwise N=10,544. Data detail in Tables 4, 7, and 10.

Figure 15. Estimated impact of timely identification and treatment on hours spent in the ICU for patients discharged alive (100% success vs. 0% success). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Full cohort; sepsis screen/vital signs N=10,543, lactate resulted N=10,113, otherwise N=10,544. Data detail in Tables 4, 7, and 10.

Figure 16. Estimated opportunity to impact hours spent in the ICU for patients discharged alive (100% success vs. current %). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Severe sepsis cohort; lactate resulted N=2,390, otherwise N=2,395. Data detail in Tables 4, 7, and 10.

Figure 17. Estimated impact of timely identification and treatment on hours spent in the ICU for patients discharged alive (100% success vs. 0% success). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Severe sepsis cohort; lactate resulted N=2,390, otherwise N=2,395. Data detail in Tables 4, 7, and 10.

Figure 18. Estimated opportunity to impact hours spent in the ICU for patients discharged alive (100% success vs. current %). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Septic shock cohort; sepsis screen/vital signs N=3,487, lactate resulted N=3,484, otherwise N=3,488. Data detail in Tables 4, 7, and 10.

Figure 19. Estimated impact of timely identification and treatment on hours spent in the ICU for patients discharged alive (100% success vs. 0% success). Point estimates and 95% confidence intervals are shown. The vertical line at zero indicates no impact. Septic shock cohort; sepsis screen/vital signs N=3,487, lactate resulted N=3,484, otherwise N=3,488. Data detail in Tables 4, 7, and 10.

REFERENCES

1. Paoli C, Reynolds M, Sinha M, Gitlin M, Crouser E. Epidemiology and Costs of Sepsis in the United States-An Analysis Based on Timing of Diagnosis and Severity Level. *Critical care medicine*. 2018;46(12).
2. Liu V, Escobar GJ, Greene JD, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. *JAMA*. 2014;312(1):90-92.
3. Danna DM. Hospital Costs Associated with Sepsis Compared with Other Medical Conditions. *Crit Care Nurs Clin North Am*. 2018;30(3):389-398.
4. Rhodes A, Evans L, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive care medicine*. 2017;43(3).
5. Yang H, Wang W, Li Y, Tian L, Jing M, Hu Y. [Application effect of 1-hour bundle in the treatment of patients with sepsis]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*. 2019;31(9):1087-1090.
6. Wang Z, Xiong Y, Schorr C, Dellinger RP. Impact of sepsis bundle strategy on outcomes of patients suffering from severe sepsis and septic shock in china. *J Emerg Med*. 2013;44(4):735-741.
7. Wang L, Ma X, He H, et al. Compliance with the Surviving Sepsis Campaign guideline 1-hour bundle for septic shock in China in 2018. *Ann Transl Med*. 2021;9(4):278.
8. Tromp M, Hulscher M, Bleeker-Rovers CP, et al. The role of nurses in the recognition and treatment of patients with sepsis in the emergency department: a prospective before-and-after intervention study. *International Journal of Nursing Studies*. 2010;47(12):1464-1473.
9. Shiramizo SC, Marra AR, Durao MS, Paes AT, Edmond MB, Pavao dos Santos OF. Decreasing mortality in severe sepsis and septic shock patients by implementing a sepsis bundle in a hospital setting. *PLoS One*. 2011;6(11):e26790.
10. Rinaldi L, Ferrari E, Marietta M, et al. Effectiveness of sepsis bundle application in cirrhotic patients with septic shock: a single-center experience. *J Crit Care*. 2013;28(2):152-157.
11. Raj SK, Panda PK, Wig N, Agarwal P, Pandey RM. Compliance with 6 h-Sepsis Resuscitation Bundle of Surviving Sepsis Campaign before and after Resident Physicians' Training: A Quality Improvement Interventional Study among Indian Patients. *J Emerg Trauma Shock*. 2019;12(1):3-9.
12. Pestana D, Espinosa E, Sanguesa-Molina JR, et al. Compliance with a sepsis bundle and its effect on intensive care unit mortality in surgical septic shock patients. *J Trauma*. 2010;69(5):1282-1287.
13. Nguyen HB, Corbett SW, Steele R, et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. *Critical Care Medicine*. 2007;35(4):1105-1112.
14. Na S, Kuan WS, Mahadevan M, et al. Implementation of early goal-directed therapy and the surviving sepsis campaign resuscitation bundle in Asia. *Int J Qual Health Care*. 2012;24(5):452-462.
15. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. *Intensive Care Med*. 2018;44(6):925-928.
16. Lehman KD. Update: Surviving Sepsis Campaign recommends Hour-1 bundle use. *Nurse Pract*. 2019;44(4):10.
17. Lefrant JY, Muller L, Raillard A, et al. Reduction of the severe sepsis or septic shock associated mortality by reinforcement of the recommendations bundle: a multicenter study. *Ann Fr Anesth Reanim*. 2010;29(9):621-628.
18. Hu B, Xiang H, Dong Y, Portner E, Peng Z, Kashani K. Timeline of sepsis bundle component completion and its association with septic shock outcomes. *J Crit Care*. 2020;60:143-151.

19. Gripp L, Raffoul M, Milner KA. Implementation of the Surviving Sepsis Campaign one-hour bundle in a short stay unit: A quality improvement project. *Intensive Crit Care Nurs*. 2021;63:103004.
20. De Miguel-Yanes JM, Munoz-Gonzalez J, Andueza-Lillo JA, Moyano-Villaseca B, Gonzalez-Ramallo VJ, Bustamante-Fermosel A. Implementation of a bundle of actions to improve adherence to the Surviving Sepsis Campaign guidelines at the ED. *Am J Emerg Med*. 2009;27(6):668-674.
21. Daniels R, Nutbeam T, McNamara G, Galvin C. The sepsis six and the severe sepsis resuscitation bundle: a prospective observational cohort study. *Emerg Med J*. 2011;28(6):507-512.
22. Carvas JM, Canelas C, Montanha G, Silva C, Esteves F. Impact of Compliance with a Sepsis Resuscitation Bundle in a Portuguese Emergency Department. *Acta Med Port*. 2016;29(2):88-94.
23. Cardoso T, Carneiro AH, Ribeiro O, Teixeira-Pinto A, Costa-Pereira A. Reducing mortality in severe sepsis with the implementation of a core 6-hour bundle: results from the Portuguese community-acquired sepsis study (SACiUCI study). *Crit Care*. 2010;14(3):R83.
24. Bray C, Kennedy C. Improving timely sepsis care using the surviving sepsis campaign one-hour bundle in a rural emergency department. *J Am Assoc Nurse Pract*. 2020;33(3):246-253.
25. Boucher JE, Carpenter D. Sepsis: Symptoms, Assessment, Diagnosis, and the Hour-1 Bundle in Patients With Cancer. *Clin J Oncol Nurs*. 2020;24(1):99-102.
26. Rhee C, Filbin M, Massaro AF, et al. Compliance with the National SEP-1 Quality Measure and Association with Sepsis Outcomes: A Multicenter Retrospective Cohort Study. *Crit Care Med*. 2018;46(10):1585-1591.
27. Rhee C, Chiotos K, Cosgrove SE, et al. Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. *Clinical Infectious Diseases*. 2020.
28. Rhee C, Filbin MR, Massaro AF, et al. Compliance With the National SEP-1 Quality Measure and Association With Sepsis Outcomes: A Multicenter Retrospective Cohort Study. *Crit Care Med*. 2018;46(10):1585-1591.
29. Pepper DJ, Sun J, Cui X, Welsh J, Natanson C, Eichacker PQ. Antibiotic- and Fluid-Focused Bundles Potentially Improve Sepsis Management, but High-Quality Evidence Is Lacking for the Specificity Required in the Centers for Medicare and Medicaid Service's Sepsis Bundle (SEP-1). *Crit Care Med*. 2019;47(10):1290-1300.
30. Miller J, Hall B, Wilson K, Cobian J. Impact of SEP-1 on broad-spectrum combination antibiotic therapy in the emergency department. *Am J Emerg Med*. 2020;38(12):2570-2573.
31. Barbash IJ, Kahn JM. Sepsis quality in safety-net hospitals: An analysis of Medicare's SEP-1 performance measure. *J Crit Care*. 2019;54:88-93.
32. Barbash IJ, Davis BS, Yabes JG, Seymour CW, Angus DC, Kahn JM. Treatment Patterns and Clinical Outcomes After the Introduction of the Medicare Sepsis Performance Measure (SEP-1). *Ann Intern Med*. 2021.
33. Barbash IJ, Davis B, Kahn JM. National Performance on the Medicare SEP-1 Sepsis Quality Measure. *Crit Care Med*. 2019;47(8):1026-1032.
34. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-810.
35. Singer M, Shankar-Hari M. qSOFA, Cue Confusion. *Annals of Internal Medicine*. 2018;168(4):293.
36. Hubbard A, Laan M. Population intervention models in causal inference. *Biometrika*. 2008;95(1).
37. Snowden JM, Rose S, Mortimer KM. Implementation of G-computation on a simulated data set: demonstration of a causal inference technique. *Am J Epidemiol*. 2011;173(7):731-738.

38. Charlson ME, Pompei P, Ales KL, MacKenzie RC. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of Chronic Diseases*. 1987;40(5):373-383.
39. Quan H, Sundarajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Medical Care*. 2005;43(11):1130-1139.
40. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *American Journal of Epidemiology*. 2011;173(6):676-682.

APPENDIX

Figure A. Relationship between time to first appearance of severe sepsis clinical criteria in the medical record and mortality